# CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cns-response-to-osimertinib-vs-standard-of-care-soc-egfr-tki-as-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Johan Vansteenkiste,Thanyanan Reungwetwattana,Kazuhiko Nakagawa,B.C. Cho,M.A. Cobo Dols,E.K. Cho,A. Bertolini,Sabine Bohnet,C. Zhou,K.H. Lee,Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andy Brown,Yuri Rukazenkov,S. Ramalingam |
| Citations | 33 |
| DOI | 10.1093/annonc/mdx729.007 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2769765347 |
| Type | article |
| Year | 2017 |

## Paper authors

- [C. Zhou](https://scholariq.org/researchers/c-zhou/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.